BRIEF published on 09/23/2026 at 21:41, 1 month 15 days ago ABIONYX Pharma publie ses résultats semestriels pour 2026 Résultats Financiers Produits Biopharmaceutiques Rapport Sur Les Revenus Recherche Sur La Septicémie Déficit En LCAT
BRIEF published on 09/23/2026 at 21:41, 1 month 15 days ago ABIONYX Pharma Reports Half-Year Results for 2026 Financial Results Biopharmaceuticals Revenue Report LCAT Deficiency Sepsis Research
PRESS RELEASE published on 09/23/2026 at 21:36, 1 month 15 days ago Informations privilégiées / Autres communiqués ABIONYX Pharma annonce ses résultats financiers du 1er semestre 2026 avec une trésorerie de 26,9 M€ avant encaissement des Crédits d’Impôt Recherche et des aides du plan France 2030, perspectives axées sur l'exécution des programmes Résultats Financiers Trésorerie Plan France 2030 ABIONYX Pharma Sepsis
PRESS RELEASE published on 09/23/2026 at 21:36, 1 month 15 days ago Inside Information / Other news releases ABIONYX Pharma announces half-year financial results for 2026 with emphasis on cash balance, revenue, and expenses. Focus on innovative therapies for sepsis and LCAT deficiency under France 2030 plan Half-year Results France 2030 Plan ABIONYX Pharma Sepsis LCAT Deficiency
BRIEF published on 08/27/2026 at 19:04, 2 months 12 days ago ABIONYX Pharma Updates on Mid-Year 2026 Financials Cash Position Financial Update Ophthalmology ABIONYX Pharma 2026 Revenue
BRIEF published on 08/27/2026 at 19:04, 2 months 12 days ago ABIONYX Pharma fait le point sur ses résultats financiers de mi-année 2026 Mise À Jour Financière Ophtalmologie ABIONYX Pharma Position De Trésorerie Recettes De 2026
PRESS RELEASE published on 08/27/2026 at 18:59, 2 months 12 days ago Inside Information / Other news releases ABIONYX Pharma updates activity and cash position for H1 2026: revenue of €1.9M, cash balance of €26.9M before Research Tax Credits and grants. Company focuses on innovative therapies for sepsis Revenue Cash Position Innovative Therapies ABIONYX Pharma Activity Update
PRESS RELEASE published on 08/27/2026 at 18:59, 2 months 12 days ago Informations privilégiées / Autres communiqués ABIONYX Pharma révèle un chiffre d’affaires consolidé de 1,9 M€ et une trésorerie de 26,9 M€ au 30 juin 2026. La société biopharmaceutique annonce des résultats financiers et une avancée dans le développement de thérapies innovantes Chiffre D'affaires Développement Trésorerie ABIONYX Pharma Thérapies Innovantes
BRIEF published on 07/06/2026 at 20:05, 4 months 2 days ago Mise à jour mensuelle d'ABIONYX sur les droits de vote Euronext Paris Capital Social Droit De Vote Mise À Jour Financière ABIONYX Pharma
BRIEF published on 07/06/2026 at 20:05, 4 months 2 days ago ABIONYX Monthly Voting Rights Update Euronext Paris Share Capital Voting Rights Financial Update ABIONYX Pharma
Published on 11/06/2026 at 22:15, 2 days 9 hours ago Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 2 days 19 hours ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 2 days 19 hours ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 2 days 19 hours ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/09/2026 at 08:05, 7 minutes ago Onodrim Industries secures $300 million Series A at $1.3 billion valuation to strengthen Europe's defence and industrial foundations
Published on 11/09/2026 at 08:00, 13 minutes ago Custodian Property Income REIT plc: Further momentum with majority share-based acquisition strategy, purchasing an £11.0m property portfolio from eight syndicated investment vehicles
Published on 11/09/2026 at 08:00, 13 minutes ago Eleving Group achieves record-high net profit of EUR 27.8 million in the first nine months of 2026
Published on 11/09/2026 at 07:00, 1 hour 13 minutes ago bioMérieux receives U.S. FDA 510(k) clearance for the latest versions of the BIOFIRE® FILMARRAY® Gastrointestinal Panels to enhance detection of gastrointestinal pathogens including norovirus
Published on 11/09/2026 at 07:00, 1 hour 13 minutes ago BIOPHYTIS ANNOUNCES THE OPERATIONAL LAUNCH OF ITS JOINT VENTURE IN CHINA
Published on 11/09/2026 at 07:00, 1 hour 13 minutes ago Biophytis annonce le démarrage opérationnel de sa co-entreprise en Chine
Published on 11/09/2026 at 07:00, 1 hour 13 minutes ago bioMérieux obtient l’autorisation 510(k) de la FDA américaine pour les dernières versions des tests BIOFIRE® FILMARRAY® Gastrointestinal Panels afin d’optimiser la détection des pathogènes gastrointestinaux, dont le norovirus
Published on 11/06/2026 at 19:06, 2 days 13 hours ago ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES OCTOBRE 2026
